Today's Date: January 29, 2023
CREDITORS COMMITTEE FILES REORGANIZATION PLAN FOR DIOCESE OF ROCKVILLE CENTRE; DIOCESE OF ROCKVILLE CENTRE FILES REORGANIZATION   •   CLEANSPARK INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers an   •   Black CannaBusiness CEO Intensive and Multi-State Cannabis Company Parallel Launch 2023 National Education Series in Pittsburgh   •   University of Phoenix College of Doctoral Studies Releases Whitepaper on Role of Demographics in Career Optimism   •   PALANTIR TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the   •   University of Phoenix Vice Provost Doris Savron Featured Guest Speaker for Greater Phoenix Chamber Mentor Program   •   Philip Morris International Inc. (PMI) Announces Agreement to Extend and Deepen Collaboration With KT&G   •   Statement by the Prime Minister on the National Day of Remembrance of the Quebec City Mosque Attack and Action against Islamopho   •   Catholics for Choice on the Murder of Tyre Nichols: Black Lives Matter is a Pro-Life Issue   •   Dollar General Announces 19,000th Store Opening   •   Susan G. Komen® Applauds House Introduction of Bipartisan Metastatic Breast Cancer Access to Care Act   •   CORRECTING and REPLACING Vibrant Emotional Health Names Dr. Tia Dole as New Chief 988 Suicide & Crisis Lifeline Officer   •   "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representin   •   BLACK HISTORY MONTH STAMP HONOURS CHLOE COOLEY   •   Trusted reusable nappy retailer commits to nationwide incentive scheme and eco education for first-time parents   •   GINKGO BIOWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Long-Term St   •   ZILLOW GROUP INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers   •   AARP The Magazine Celebrates the 21st Annual Movies for Grownups® Awards   •   The International Fellowship of Christians and Jews Celebrating 40th Anniversary in 2023   •   Dame Shellie Hunt Founder of the Women of Global Change Honored with Humanitarian Doctorate in London
Bookmark and Share

Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022

MARSEILLE, France , December 09 /Businesswire/ - Regulatory News:

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at December 1, 2022:

Total number of shares outstanding:

 

80,812,069 ordinary shares

 

 

6,514 Preferred Shares 2016

7,581 Preferred Shares 2017

Total number of theoretical voting rights (1):

Total number of exercisable voting rights (2):

 

80,969,909

80,951,334

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code

Ticker code

LEI

 

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.


STORY TAGS: Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, France, Europe, Stock Sale/Buyback, France Disclosure,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News